XENE

Over the past six months, Xenon Pharmaceuticals' stock (XENE) has increased by 25.9%, trading at $56.44 as of May 9, 2026. In March 2026, positive Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures were reported, supporting a planned NDA submission to the FDA in Q3 2026. In Q1 2026, Xenon raised $837.6 million in net equity proceeds, increasing cash reserves to $1.34 billion. Xenon reported its Q1 2026 financial results, showing a net loss of $102.3 million, and the stock has experienced some volatility as investors question the timeline for its epilepsy drug pipeline to translate into real revenue.